Scarica l'app Stockscreener
3.07
3.15%
-0.10
Neurosense Therapeutics Ltd Borsa (NRSN) Ultime notizie
$1 bid-price compliance regained, but NeuroSense (Nasdaq: NRSN) still faces a listing deficiency. - Stock Titan
The $1 share-price rule is met, but NeuroSense still faces another Nasdaq listing test. - Stock Titan
NRSN Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 7.14%Earnings Forecast Report - https://www.dars.gov.et/
NeuroSense Regains Nasdaq Bid Price Compliance, Appeals Market Value Delisting Notice - The Globe and Mail
The $1 bid-price hurdle is cleared, but NeuroSense (Nasdaq: NRSN) still faces delisting. - Stock Titan
NeuroSense Provides Update on Nasdaq Listing Compliance - Moomoo
A $35 million Nasdaq market-value rule remains unmet; NeuroSense plans to seek more time. - Stock Titan
NeuroSense Provides Update on Nasdaq Listing Compliance - TradingView
Without delays, cash won't fund 12 months under NeuroSense's (NASDAQ: NRSN) original development plan. - Stock Titan
NeuroSense Provides Business Update and Progress for the First Half of 2026 - Morningstar
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq - The Globe and Mail
NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq - The Globe and Mail
NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq - TipRanks
12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com
NeuroSense (NASDAQ: NRSN) cuts share count to 1.9M in 1-for-20 split - Stock Titan
NRSN 6-K & SEC Filings - Yahoo! Finance Canada
Why Is NeuroSense (NASDAQ:NRSN) in Focus Before Tuesday’s Open? - kalkinemedia.com
Amyotrophic Lateral Sclerosis Pipeline 2026: FDA Approvals, - openPR.com
NeuroSense Therapeutics (NRSN) Slips 1.24% to $0.41, Hovering Near Key Support at $0.39Parabolic SAR - dars.gov.et
NeuroSense Therapeutics (NRSN) Slips 1.24% to $0.41, Hovering Near Key Support at $0.39Trade Entry Signals - dars.gov.et
NeuroSense Therapeutics (NRSN) Slips 1.24% to $0.41, Hovering Near Key Support at $0.39Ascending Triangle - dars.gov.et
NRSN Q2'26 Earnings: EPS estimate is (0.20) USD - TradingView
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS - Morningstar
NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval - TipRanks
NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval - Benzinga
NeuroSense (NRSN) gains 12‑month mandate for reverse share split - Stock Titan
NeuroSense Therapeutics Ltd. Warrant (NRSNW) Peer Comparison – Compare with Others - Value Research
NeuroSense Therapeutics Ltd. Revenue Breakdown – NASDAQ:NRSN - TradingView
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session - vinanet.vn
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session: Support at $0.36 and Resistance at $0.40 Frame the Range for the Current SessionValue Area High - careplusvn.com
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session: Support at $0.36 and Resistance at $0.40 Frame the Range for the Current SessionThrowback Trade - siam.in
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session - dars.gov.et
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session - dars.gov.et
Neurosense Therapeutics Stock Price Forecast. Should You Buy NRSN? - StockInvest.us
NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts - The Globe and Mail
Amyotrophic Lateral Sclerosis Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight - openPR.com
NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts - TipRanks
NeuroSense Issues CEO Letter to Shareholders - Nasdaq
NeuroSense Issues CEO Letter to Shareholders - webull.com
NeuroSense Therapeutics (NRSN) Slips to $0.47 as Bulls Defend Key Support FloorNHNL Ratio - dars.gov.et
NeuroSense Therapeutics (NRSN) Slips to $0.47 as Bulls Defend Key Support FloorAnchored VWAP - dars.gov.et
Global Neurodegenerative Disease Market is Expected to - GlobeNewswire
NeuroSense Therapeutics (NRSN) Dips 1.6% to $0.49, Testing Key Support at $0.47PCR Moving Average - dars.gov.et
NeuroSense Therapeutics (NRSN) Dips 1.6% to $0.49, Testing Key Support at $0.47Price Surge Stocks - dars.gov.et
NRSN Q2 2025 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Pipeline AdvancesMid-Term Outlook - dars.gov.et
NeuroSense Advances PrimeC Toward December 2026 Health Canada Filing After Completing Pre-NDS Process - TipRanks
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - GuruFocus
Health Canada review path for PrimeC: NeuroSense (NASDAQ: NRSN) - Stock Titan
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):